Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 26/5/2020
SIETES contiene 93011 citas

 
 
 1 a 20 de 30 siguiente >>
Presentar resultados
Seleccionar todas
1.Tiene citas relacionadas
Sternlicht H, Bakris GL. Spironolactone for resistant hypertension—hard to resist?. Lancet 2015;386:2032-4. [Ref.ID 99769]
2.Tiene citas relacionadas Cita con resumen
Bakris GL, Pitt B, Weir MR, Freeman MW, Mayo MR, Garza D, Stasiv Y, Zawadzki R, Berman L, Bushinsky DA, for the AMETHYST-DN Investigators. Effect of patiromer on serum potassium level in patients with hyperkalemia and diabetic kidney disease: the AMETHYST-DN randomized clinical trial. JAMA 2015;314:151-61. [Ref.ID 99346]
3.Tiene citas relacionadas Cita con resumen
Zannad F, Cannon CP, Cushman WC, Bakris GL, Menon V, Perez AT, Fleck PR, Mehta CR, Kupfer S, Wilson C, Lam H, White WB, for the EXAMINE Investigators. Heart failure and mortality ocutcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial. Lancet 2015;385:2067-76. [Ref.ID 99158]
4.Tiene citas relacionadas Cita con resumen
Weir MR, Bakris GL, Bushinsky DA, Garza DG, Stasiv Y, Wittes J, Christ-Schmidt H, Berman L, Pitt B, for the OPAL-HK Investigators. Patiromer in patients with kidney disease and hyperkalaemia receiving RAAS inhibitors. N Engl J Med 2015;372:211-21. [Ref.ID 98710]
5.Tiene citas relacionadas Cita con resumen
White WB, Cannon CP, Heller SR, Nissen SE, Bergenstal RM, Bakris GL, Perez AT, Fleck PR, Mehta CR, Kupfer S, Wilson C, Cushman WC, Zannad F, for the EXAMINE Investigators. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med 2013;369:1327-35. [Ref.ID 96331]
6.Tiene citas relacionadas Cita con resumen
Nicholls SJ, Bakris GL, Kastelein JJP, Menon V, Williams B, Ambrecht J, Brunel P, Nicolaides M, Hsu A, Hu B, Fang H, Puri R, Uno K, Kataoka Y, Bash D, Nissen SE. Effect of aliskiren on progression of coronary disease in patients with prehypertension: the AQUARIUS randomized clinical trial. JAMA 2013;310:1135-44. [Ref.ID 96112]
7.Tiene citas relacionadas
Weber MA, Bakris GL, Weir MR, Jamerson K. Obesity, blood pressure, and cardiovascular outcomes - Authors' reply. Lancet 2013;381:1982. [Ref.ID 95608]
8.Tiene citas relacionadas Cita con resumen
Weber MA, Jamerson KB, Bakris GL, Weir MR, Zappe D, Zhang Y, Dahlof B, Velázquez EJ, Pitt B. Effects of body size and hypertension treatments on cardiovascular event rates: subanalysis of the ACCOMPLISH randomised controlled trial. Lancet 2013;381:537-45. [Ref.ID 94952]
10.Tiene citas relacionadas
Appel LJ, Wright Jr JT, Greene T, Agodoa LY, Astor BC, Bakris GL, Cleveland WH, Charleston J, Contreras G, Faulkner ML, Gabbai FB, Gassman JJ, Hebert LA, Jamerson K, Kopple JD, Kusek JW, Lash JP, Lea JP, Lewis JB, Kipkowitz MS, Massry SG, Miller ER, Norris K, Phillips RA, Pogue VA, Randall OS, Rostand G, for the AASK Collaborative Research Group. Intensive blood-pressure control in hypertensive chronic kidney disease. N Engl J Med 2010;363:918-29. [Ref.ID 89297]
11. Cita con resumen
Cooper-DeHoff RM, Gong Y, Handberg EM, Bavry AA, Denardo SJ, Bakris GL, Pepine CJ. Tight blood pressure control and cardiovascular outcomes among hypertensive patients with diabetes and coronary artery disease. JAMA 2010;304:61-8. [Ref.ID 88883]
12.Tiene citas relacionadas Cita con resumen
Bakris GL, Sarafidis PA, Weir MR, Dahlöf B, Pitt B, Jamerson K, Velázquez EJ, Staikos-Byrne L, Kelly RY, Shi V, Chiang Y-T, Weber MA, for the ACCOMPLISH trial investigators. Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial. Lancet 2010;375:1173-81. [Ref.ID 88236]
13.Tiene citas relacionadas Cita con resumen
Sarafidis PA, Bakris GL. Does evidence support renin-angiotensin system blockade for slowing nephropathy progression in elderly persons?. Ann Intern Med 2009;150:731-3. [Ref.ID 85910]
14.Tiene citas relacionadas Cita con resumen
Jamerson K, Weber MA, Bakris GL, Dahlöf B, Pitt B, Shi V, Gupte J, Gatlin M, Velázquez EJ, for the ACCOMPLISH trial investigators. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med 2008;359:2417-8. [Ref.ID 84603]
16.Tiene citas relacionadas
Bell DS, Bakris GL. Carvedilol, metoprolol, and insulin resistance. In reply. JAMA 2005;293:1190. [Ref.ID 73035]
17. Cita con resumen
Abbott KC, Trespalacios FC, Agodoa LY, Taylor AJ, Bakris GL. ß-blocker use in long-term dialysis patients. Association with hospitalized heart failure and mortality. Arch Intern Med 2004;164:2465-71. [Ref.ID 72265]
18. Cita con resumen
Bakris GL, Fonseca V, Katholi RE, McGill JB, Messerli FH, Phillips R A, Raskin P, Wright JT, Oakes R, Lukas MA, Anderson KM, Bell DSH, for the GEMINI Investigators. Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension. A randomized controlled trial. JAMA 2004;292:2227-36. [Ref.ID 71847]
19.Tiene citas relacionadas Cita con resumen
Pepine C J, Handberg EM, Cooper-DeHoff RM, Marks RG, Kowey P, Messerli FH, Mancia G, Cangiano JL, Garcia-Barreto D, Keltai M, Erdine S, Bristol H A, Kolb H R, Bakris GL, Cohen JD, Parmley W W, for the INVEST Investigators. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease: The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA 2003;290:2805-16. [Ref.ID 68384]
20.
Bakris GL, Weir MR, Shanifar S, Zhang Z, Douglas J, van Dijk DJ, Brenner BM, for the RENAAL Study Group. Effects of blood pressure level on progression of diabetic nephropathy. Arch Intern Med 2003;163:1555-65. [Ref.ID 66719]
Seleccionar todas
 
 1 a 20 de 30 siguiente >>